Literature DB >> 23245672

A unique pattern of INI1 immunohistochemistry distinguishes synovial sarcoma from its histologic mimics.

Michael A Arnold1, Christina A Arnold, Guang Li, Uisoo Chae, Rana El-Etriby, Chyi-Chia Richard Lee, Maria Tsokos.   

Abstract

The absence of INI1 (SMARCB1, hSNF5, BAF47) immunohistochemical reactivity is a central feature of malignant rhabdoid tumor, renal medullary carcinoma, and epithelioid sarcoma. We characterized INI1 immunoreactivity in synovial sarcoma (49 cases) in comparison with its closest histologic mimics (68 cases). We observed a unique pattern of decreased INI1 immunoreactivity with a high specificity (100%) and sensitivity (86%) for synovial sarcoma and particular sensitivity for poorly differentiated subtypes of synovial sarcoma (94%; 16/17 cases). Decreased INI1 immunoreactivity was not seen in any of the other lesions we examined, including 14 cases of Ewing sarcoma and 22 cases of malignant peripheral nerve sheath tumor. Furthermore, decreased INI1 immunoreactivity is distinct from the complete absence of INI1 immunoreactivity seen in malignant rhabdoid tumor or other INI1-negative neoplasms. We propose that this distinct INI1 immunohistochemical pattern serves as a useful diagnostic tool to provide preliminary results before molecular test results are available, especially in cases of poorly differentiated synovial sarcoma and in cases where limited material precludes confirmatory molecular studies. Awareness of this unique pattern is critical to avoid misinterpreting decreased INI1 immunoreactivity as a complete absence of INI1 and, consequently, misdiagnosing synovial sarcoma as an INI1-negative neoplasm.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245672     DOI: 10.1016/j.humpath.2012.08.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Cystic synovial sarcoma of the pleura mimicking a cystic thymoma: a case report illustrating the role of decreased INI-1 expression in differential diagnosis.

Authors:  Shogo Tajima; Tsuyoshi Takahashi; Toru Itaya; Kenji Koda; Hiroshi Neyatani
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Beware of immunohistochemistry--report of a cytokeratin-, desmin- and INI-1-negative pelvic desmoplastic small round cell tumor in a 51 year old woman.

Authors:  Gwyneth St Soon; Fredrik Petersson
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  What is new in epithelioid soft tissue tumors?

Authors:  Abbas Agaimy
Journal:  Virchows Arch       Date:  2019-11-04       Impact factor: 4.064

4.  Leiomyosarcoma: a rare tumor of the thyroid.

Authors:  Jantima Tanboon; Phawin Keskool
Journal:  Endocr Pathol       Date:  2013-09       Impact factor: 3.943

5.  The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.

Authors:  Matthew J McBride; John L Pulice; Hannah C Beird; Davis R Ingram; Andrew R D'Avino; Jack F Shern; Gregory W Charville; Jason L Hornick; Robert T Nakayama; Enrique M Garcia-Rivera; Dejka M Araujo; Wei-Lien Wang; Jen-Wei Tsai; Michelle Yeagley; Andrew J Wagner; P Andrew Futreal; Javed Khan; Alexander J Lazar; Cigall Kadoch
Journal:  Cancer Cell       Date:  2018-05-31       Impact factor: 31.743

6.  Identification of novel SSX1 fusions in synovial sarcoma.

Authors:  Akihiko Yoshida; Yasuhito Arai; Kaishi Satomi; Takashi Kubo; Eijitsu Ryo; Yuko Matsushita; Natsuko Hama; Kazuki Sudo; Motokiyo Komiyama; Yasushi Yatabe; Tatsuhiro Shibata; Hitoshi Ichikawa; Koichi Ichimura; Akira Kawai; Taisuke Mori
Journal:  Mod Pathol       Date:  2021-09-09       Impact factor: 7.842

7.  Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Authors:  Simon Wöhrle; Andreas Weiss; Moriko Ito; Audrey Kauffmann; Masato Murakami; Zainab Jagani; Anne Thuery; Beatrice Bauer-Probst; Flavia Reimann; Christelle Stamm; Astrid Pornon; Vincent Romanet; Vito Guagnano; Thomas Brümmendorf; William R Sellers; Francesco Hofmann; Charles W M Roberts; Diana Graus Porta
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

8.  BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.

Authors:  Sho Watanabe; Akihiko Shimomura; Takashi Kubo; Masaya Sekimizu; Takuji Seo; Shun-Ichi Watanabe; Akira Kawai; Noboru Yamamoto; Kenji Tamura; Takashi Kohno; Hitoshi Ichikawa; Akihiko Yoshida
Journal:  Mod Pathol       Date:  2020-04-01       Impact factor: 7.842

9.  A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.

Authors:  Jinxiu Li; Timothy S Mulvihill; Li Li; Jared J Barrott; Mary L Nelson; Lena Wagner; Ian C Lock; Amir Pozner; Sydney Lynn Lambert; Benjamin B Ozenberger; Michael B Ward; Allie H Grossmann; Ting Liu; Ana Banito; Bradley R Cairns; Kevin B Jones
Journal:  Cancer Discov       Date:  2021-06-02       Impact factor: 39.397

10.  A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.

Authors:  Esther Baranov; Matthew J McBride; Andrew M Bellizzi; Azra H Ligon; Christopher D M Fletcher; Cigall Kadoch; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.